Compared with that in the low-proliferation Ki-67 group, the incidence of epilepsy in glioma patients in the high-proliferation Ki-67 group was significantly reduced (P = 0.006), and the risk was reduced by 75% (OR = 0.25; 95% CI: 0.10, 0.68). This evidence concerns the gene MKI67 and central nervous system cancer.